PE20060678A1 - Formas cristalinas de derivados de etilamina y procedimiento de preparacion de los mismos - Google Patents

Formas cristalinas de derivados de etilamina y procedimiento de preparacion de los mismos

Info

Publication number
PE20060678A1
PE20060678A1 PE2005000372A PE2005000372A PE20060678A1 PE 20060678 A1 PE20060678 A1 PE 20060678A1 PE 2005000372 A PE2005000372 A PE 2005000372A PE 2005000372 A PE2005000372 A PE 2005000372A PE 20060678 A1 PE20060678 A1 PE 20060678A1
Authority
PE
Peru
Prior art keywords
compound
procedure
preparation
monoclorhydrate
polymorph
Prior art date
Application number
PE2005000372A
Other languages
English (en)
Inventor
Darren Michael Caine
Ian Leonard Paternoster
Peter David Penberthy Shapland
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34963396&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20060678(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0407521A external-priority patent/GB0407521D0/en
Priority claimed from GB0411688A external-priority patent/GB0411688D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PE20060678A1 publication Critical patent/PE20060678A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/42—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/43—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

REFERIDA A UN PROCEDIMIENTO PARA LA PREPARACION DE UNA SAL MONOCLORHIDRATO DEL COMPUESTO DE FORMULA I, EN LA QUE *C Y **C SON ATOMOS DE CARBONO ASIMETRICOS; DONDE DICHO PROCEDIMIENTO COMPRENDE: A) PONER EN CONTACTO UN COMPUESTO DE FORMULA (II), EN LA QUE P1 ES UN GRUPO PROTECTOR DE HIDROXILO Y P2 Y P3 SON H O UN GRUPO PROTECTOR; CON UN ACIDO DEBIL PARA EFECTUAR LA PROTONACION SELECTIVA, B) PONER EN CONTACTO EL PRODUCTO DE (A) CON UNA FUENTE DE IONES CLORURO PARA EFECTUAR EL INTERCAMBIO DE ANIONES, C) DESPROTECCION PARA ELIMINAR P1, Y CUANDO SEA NECESARIO P2 Y P3, D) AISLAR EL COMPUESTO I COMO EL MONOCLORHIDRATO, Y DE FORMA OPCIONAL E) CRISTALIZAR O RECRISTALIZAR EL COMPUESTO I. TAMBIEN ESTA REFERIDA A LA FORMA CRISTALINA (POLIMORFA) DE LA SAL MONOCLORHIDRATO DEL COMPUESTO Ia. DICHO POLIMORFO ES AGONISTA DEL ADRENORECEPTOR BETA 2 Y ES UTIL PARA EL TRATAMIENTO DE ENFERMEDADES ASOCIADAS A LA OBSTRUCCION PULMONAR, INFECCIONES DEL TRACTO RESPIRATORIO O ENFERMEDADES DEL TRACTO RESPIRATORIO SUPERIOR
PE2005000372A 2004-04-02 2005-03-31 Formas cristalinas de derivados de etilamina y procedimiento de preparacion de los mismos PE20060678A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0407521A GB0407521D0 (en) 2004-04-02 2004-04-02 Chemical process
GB0411688A GB0411688D0 (en) 2004-05-25 2004-05-25 Chemical process
US57446704P 2004-05-26 2004-05-26

Publications (1)

Publication Number Publication Date
PE20060678A1 true PE20060678A1 (es) 2006-08-02

Family

ID=34963396

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000372A PE20060678A1 (es) 2004-04-02 2005-03-31 Formas cristalinas de derivados de etilamina y procedimiento de preparacion de los mismos

Country Status (13)

Country Link
US (1) US7846973B2 (es)
EP (1) EP1730104A1 (es)
JP (1) JP2007530652A (es)
AR (1) AR052301A1 (es)
AU (1) AU2005227733A1 (es)
BR (1) BRPI0509382A (es)
CA (1) CA2561400A1 (es)
IL (1) IL178064A0 (es)
MA (1) MA28558B1 (es)
NO (1) NO20064884L (es)
PE (1) PE20060678A1 (es)
TW (1) TW200536814A (es)
WO (1) WO2005095328A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006066907A1 (en) * 2004-12-21 2006-06-29 Glaxo Group Limited Pharmaceutical formulations
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
BRPI0906838A2 (pt) 2008-01-11 2015-07-14 Novartis Ag Pirimidinas como inibidores de quinase
WO2011061527A1 (en) 2009-11-17 2011-05-26 Astrazeneca Ab Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
IT1399912B1 (it) * 2010-04-29 2013-05-09 Lundbeck Pharmaceuticals Italy S Pa Processo di preparazione di ritodrina cloridrato.
JP5645762B2 (ja) * 2010-06-29 2014-12-24 日本ポリプロ株式会社 ポリオレフィンの結晶性分布分析方法およびその装置
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
JP5959541B2 (ja) 2011-02-25 2016-08-02 ノバルティス アーゲー Ｔｒｋ阻害剤としてのピラゾロ［１，５−ａ］ピリジン
GB201212081D0 (en) * 2012-07-06 2012-08-22 Kalvista Pharmaceuticals Ltd New polymorph

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2064336B (en) 1979-12-06 1984-03-14 Glaxo Group Ltd Device for dispensing medicaments
US4353656A (en) 1980-10-14 1982-10-12 Xerox Corporation Moving coil, multiple energy print hammer system including a closed loop servo
DE3274065D1 (de) 1981-07-08 1986-12-11 Draco Ab Powder inhalator
GB2169265B (en) 1982-10-08 1987-08-12 Glaxo Group Ltd Pack for medicament
GR79615B (es) 1982-10-08 1984-10-31 Glaxo Group Ltd
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
US4811731A (en) 1985-07-30 1989-03-14 Glaxo Group Limited Devices for administering medicaments to patients
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
AU677776B2 (en) 1992-04-02 1997-05-08 Smithkline Beecham Corporation Compounds useful for treating allergic and inflammatory diseases
US5495054A (en) 1994-05-31 1996-02-27 Sepracor, Inc. Tetrahydroindeno[1,2-D][1,3,2]oxazaboroles and their use as enantioselective catalysts
US6040344A (en) 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
GB9700226D0 (en) 1997-01-08 1997-02-26 Glaxo Group Ltd Inhalation device
UA73965C2 (en) 1999-12-08 2005-10-17 Theravance Inc b2 ADRENERGIC RECEPTOR ANTAGONISTS
OA11558A (en) 1999-12-08 2004-06-03 Advanced Medicine Inc Beta 2-adrenergic receptor agonists.
US6632666B2 (en) 2000-01-14 2003-10-14 Biolife Solutions, Inc. Normothermic, hypothermic and cryopreservation maintenance and storage of cells, tissues and organs in gel-based media
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
GB0201677D0 (en) 2002-01-25 2002-03-13 Glaxo Group Ltd Medicament dispenser
TW200409746A (en) 2002-07-26 2004-06-16 Theravance Inc Crystalline β2 adrenergic receptor agonist
PL375993A1 (en) 2002-09-16 2005-12-12 Glaxo Group Limited Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors
TW200510277A (en) * 2003-05-27 2005-03-16 Theravance Inc Crystalline form of β2-adrenergic receptor agonist

Also Published As

Publication number Publication date
KR20070000508A (ko) 2007-01-02
WO2005095328A1 (en) 2005-10-13
JP2007530652A (ja) 2007-11-01
CA2561400A1 (en) 2005-10-13
NO20064884L (no) 2006-10-26
TW200536814A (en) 2005-11-16
IL178064A0 (en) 2006-12-31
US20100063157A1 (en) 2010-03-11
BRPI0509382A (pt) 2007-09-18
AU2005227733A1 (en) 2005-10-13
MA28558B1 (fr) 2007-04-03
EP1730104A1 (en) 2006-12-13
AR052301A1 (es) 2007-03-14
US7846973B2 (en) 2010-12-07

Similar Documents

Publication Publication Date Title
PE20060678A1 (es) Formas cristalinas de derivados de etilamina y procedimiento de preparacion de los mismos
BR0201437A (pt) Processo para preparar derivados de 9-desoxo-9a-aza-9a-homoeritromicina a 4"-substituìdos"
BR112012012529A2 (pt) composto indol e seu uso farmacêutico
WO2008062905A3 (en) Heteromonocyclic compound and use thereof
CO6220955A2 (es) Una composicion farmaceutica que contiene (a) n1-(5-cloropiridin-2-il)-n2-((1s,2r,4s)-4-[dimetilamino)carbonil]-2-{[(5-metil-4,5,6,7-tetrahidrotiazol[5,4-c]piridin-2-il) carbonil] amino} coclohexil)etanodiamida
BRPI0410477A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, método para a profilaxia ou tratamento de uma condição quiral em um mamìfero, formulação farmacêutica, combinação, uso de um composto, e, processo para preparar um composto
WO2008131149A3 (en) Crystal forms of saxagliptin and processes for preparing same
EA201101672A1 (ru) Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина
EA201391486A1 (ru) Способы и композиции для лечения болезни паркинсона
NZ597645A (en) Compositions containing berberine or analogs thereof for treating rosacea or red face related skin disorders
EP2639229A3 (en) Thiazole Derivative and use thereof as VAP-1 Inhibitor
WO2010107807A3 (en) Compounds for treating inflammation and pain
BRPI0508392A (pt) materiais e métodos para tratar distúrbios de coagulação
CL2008003326A1 (es) Compuestos derivados de [(2r)-3-[2-(5-fluoro-4-pirimidinil)hidrazino]-3-oxopropil]hidroxiformamida, formas polimorficas 1, 2 y 3 de dichos compuestos; composicion farmaceutica; y su uso en el tratamiento de una enfermedad bacteriana del oido, sinusitis, infeccion del tracto respiratorio superior, entre otras.
WO2006051314A3 (en) Guanidine derivatives as inhibitors of ddah
MX2012001529A (es) Derivados de 3-heteroaril-metil-imidazo-[1,2-b]-piridazin-6-ilo como moduladores de cinasa de tirosina c-met.
WO2008071961A8 (en) 2-quinolinone and 2-quinoxalinone- derivatives and their use as antibacterial agents
BR112014008783A2 (pt) compostos para o tratamento e profilaxia da doença causada por vírus sincicial respiratório
TN2014000031A1 (en) Use of organic compound for the treatment of noonan syndrome
BRPI0712312A2 (pt) Composto, processo para a produção do mesmo, composição farmacêutica, agente antimicrobiano, agente anti-mrsa, método para a prevenção ou o tratamento de uma doença infecciosa, e, uso do composto
WO2011037833A3 (en) Novel n-benzylamide substituted derivatives of 2-(acylamido)acetic acid and 2-(acylamido)propionic acids: potent neurological agents
WO2010019203A8 (en) Antifungal agents
MX2009011818A (es) Formulaciones de aminoacido n-halogenado con compuestos anti-inflamatorios.
MX2022011179A (es) Uso medico de daridorexant.
EP2772481A8 (en) Novel compound as kcnq potassium channel agonist, preparation method therefor and use thereof

Legal Events

Date Code Title Description
FC Refusal